Special Interest Groups

Developing Strategies for a Sustainable Career in Pathology


This schedule is preliminary and subject to change




Special Interest Group Meetings


Special Interest Group Meetings



Special Interest Group Meetings

Nephropathology SIG
Saturday June 10, 1830-1930


Chair: Laurette Geldenhuys, Dalhousie University




  1. Approval of Agenda
  2. Approval of Minutes – July 9, 2016
  3. Website
  4. Guidelines
  5. Registries
  6. Other business
    1. EQA Program
    2. Diploma Program
    3. Practice survey
  7. Interesting cases
  8. Next meeting – Quebec City, 2018
  9. Adjournment

Back to top


Canadian Network of Uropathology SIG: A Case Based Interactive Approach to Challenging GU Diagnoses
Saturday June 10, 1830-2030


Michelle Downes, Sunnybrook Health Sciences Centre

Manal Gabril, London Health Sciences Centre

George M. Yousef, University of Toronto, St. Michael’s Hospital



At the end of this session, participants will be able to:

  • Identify new and emerging entities in GU pathology.
  • Differentiate between similar appearing tumours.
  • Integrate immunoprofile and morphology to arrive at a diagnosis.
  • Explain how a favoured diagnosis was reached.

This is an interactive, case based workshop led by two practicing GU pathologists. Cases covering a variety of GU pathologic entities will be reviewed and discussed over a 90 minute period. Each case will be presented and participants will vote on most likely diagnosis from a list of provided differential diagnoses. Following voting, the final diagnosis will be discussed with supportive evidence as to why this was the preferred diagnosis. The differential diagnoses will be discussed, highlighting relevant positive and negative findings. There will be the opportunity to interact and ask questions after each case and also at the end of the session.

Back to top


Gynecological Pathology SIG
Monday June 12, 1000-1200


Chair: Carlos Parra-Herran, Sunnybrook Health Sciences Centre, University of Toronto



Introduction and Update on Endometrial Biopsy Reporting

Carlos Parra-Herran, Sunnybrook Health Sciences Centre, University of Toronto



BRCA Testing in Ovarian Cancer – the Role of Pathology

Bojana Djordjevic, Sunnybrook Health Sciences Centre, University of Toronto



At the end of this session, participants will be able to:

  • Describe the clinical relevance of identifying patients with BRCA mutations.
  • Assess the pathological phenotype of BRCA mutation associated high grade serous carcinoma.
  • Compare germline and somatic BRCA mutation testing in terms of their respective advantages and disadvantages.
  • Discuss the logistical challenges and approaches to population.

Up to 20% of high grade serous carcinomas have a mutation in BRCA 1 or BRCA 2 genes. Recent studies have shown that such tumors are also associated with a particular pathological phenotype. To date, the referral rates of patients with high grade serous carcinoma to genetic counseling have been low and associated with long turnaround times. The widespread adoption of next generation sequencing technology is creating an emerging opportunity for pathology laboratories to play a role in BRCA gene mutation testing of on formalin fixed and paraffin embedded tissue. Utilization of somatic mutation testing, both as a triage tool for germline mutation testing and for identifying patients who would benefit from PARP inhibitor therapy, will be outlined. Logistical challenges and approaches to population-based BRCA testing will be discussed. The session will be of value to pathology residents and general and anatomic pathologists.



Pathology of the Female Peritoneum, A Practical Review

Anais Malpica, The University of Texas MD Anderson Cancer Center



At the end of this session, participants will be able to:

  • Interpret benign entities occurring in the female peritoneum that can potentially represent a diagnostic challenge.
  • List the clinicopathologic features of well differentiated papillary mesothelioma.
  • Describe the clinicopathologic features of peritoneal inclusion cysts.
  • Summarize the morphologic features and ancillary tests required for the diagnosis of malignant mesothelioma.

In this session, we will cover a wide range of lesions detected in the female peritoneum from non-mesothelial, benign lesions that can represent a diagnostic challenge (i.e., endometriosis , keratin granulomas, histiocytic aggregates, etc.) to malignant mesothelioma and entities to be considered in its differential diagnosis. The review includes a discussion of the clinicopathologic features and ancillary studies to ensure the proper diagnosis of each entity.



Uterine Mesenchymal Tumors: Changes, Controversies, and Common Ground

Bradley Quade, Harvard Medical School, Brigham and Women’s Hospital



At the end of this session, participants will be able to:

  • Recognize mesenchymal tumors newly or recently described in the uterus.
  • Summarize the strategies that facilitate their distinction from well-recognized morphologically similar tumors.
  • Define genotype-phenotype relationships associated with various female reproductive tract mesenchymal tumors.
  • Discuss how knowledge gaps in our understanding of smooth muscle tumor biology impact the approach to pathological diagnosis.

The collection of recognized mesenchymal tumors found in the uterus and the approach to their diagnosis has been relatively stable for many years, but recently, new tumor types and genetic drivers (viz., PECOMA, IMT, high grade ESS, HLRCC) have been described. Consequently, our diagnostic practice must expand. This presentation will discuss the strategies and tools to enable recognition and diagnosis of the growing spectrum of uterine meschymal tumors. While doing so, we will also spotlight the underlying genetic features, particularly for smooth muscle tumors, and discuss how the gaps in our understanding of their pathogenesis impact every day pathological diagnosis.

Back to top